12:00 AM
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BCX4161: Preliminary Phase IIa data

Preliminary data from the crossover, German and U.K. Phase IIa OPuS-1 trial in 24 HAE patients with an attack frequency of >=1 attack per week showed that prophylactic treatment with thrice-daily 400 mg oral BCX4161 for 28 days met the primary endpoint of reducing the mean frequency of angioedema attacks vs. placebo (0.82 vs. 1.27 attacks per week, p<0.001). BCX4161 also met the secondary endpoint of increasing...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >